UK Biobank cohort of 280000 adults records 20% lower dementia incidence after recombinant shingles vaccination

The study extracted vaccination records and ICD-coded dementia outcomes from 282000 adults aged 50-plus between 2017 and 2023. Cox models adjusted for age, sex, education, and prior health service use produced a hazard ratio of 0.80 for all-cause dementia among vaccinated versus unvaccinated participants. Sensitivity checks using influenza vaccination as negative control left the shingles association intact.

Prior observational work on live-attenuated zoster vaccine reported similar point estimates in Wales and Australia cohorts, yet residual confounding by health-seeking behavior remains unmeasured. No randomized trial has tested dementia as primary endpoint; mechanistic hypotheses center on reduced herpesvirus reactivation and lowered neuroinflammation rather than direct neuroprotection.

Operational consequence for health systems is immediate eligibility expansion for adults over 65 already targeted by national shingles programs. Cost-effectiveness models will require incorporation of dementia incidence data from ongoing Phase IV surveillance rather than extrapolation from existing cardiovascular endpoints.